### Edgar Filing: DRMANAC RADOJE T - Form 4/A

DRMANAC	C RADOJE T												
Form 4/A													
August 26, 2	2011												
FORM	ЛΔ											B APPROV	'AL
Washington, D.C. 20549										N OMB Number	: 323	3235-0287	
Check this box									Expires	Janua	ary 31, 2005		
Subject to Section 16. Form 4 or				ANGES IN BENEFICIAL OW SECURITIES							Estimat burden	Estimated average burden hours per response (	
Form 5 obligatio may cor <i>See</i> Instr 1(b).	ons Section 17(	(a) of the l	Public U	Jtility	Hol		mpan	y /	Act of	e Act of 1934, f 1935 or Sectio 40	on		
(Print or Type	Responses)												
DRMANAC RADOJE T Syr				. Issuer Name <b>and</b> Ticker or Trading mbol OMPLETE GENOMICS INC NOM]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) 3. Da (Mon				Date of Earliest Transaction onth/Day/Year) 24/2011						Director 10% Owner X Officer (give title Other (specify below) below)			
2071 51112	KLIN COURT		06/24/2	2011						Chief	Scientific C	Officer	
				mendment, Date Original Month/Day/Year) /2011						<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>			
MOUNTA	111  VIL W, CA 94	043								Person			
(City)	(State)	(Zip)	Tal	ole I - N	on-]	Derivativ	e Secu	riti	es Acq	uired, Disposed o	of, or Benefi	cially Own	ed
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year)			3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or						5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	wnership Indirect orm: Beneficia irect (D) Ownersh Indirect (Instr. 4)		
C				Code	V	Amoun	(D	)	Price	(Instr. 5 and 1)			
Common Stock, \$0.001 par value	08/24/2011			D		240,000	) D	1	\$ 8.19 (1)	188,666	Ι	By Farr Trust <u>(2</u>	
Common Stock, \$0.001 par value										13,333	Ι	By Corpora	ation

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)

#### Edgar Filing: DRMANAC RADOJE T - Form 4/A

# required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D)	;	ate	7. Title Amoun Underl Securit (Instr.	nt of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	(Instr. 3, 4, and 5)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(11150

## **Reporting Owners**

Reporting Owner Name / Address	Relationships								
	Director	10% Owner	Officer	Other					
DRMANAC RADOJE T 2071 STIERLIN COURT MOUNTAIN VIEW, CA 94043			Chief Scientific Officer						
Signatures									
/s/ Ajay Bansal, Attorney in Fact Drmanac	je	08/26/2011							
<u>**</u> Signature of Reporting Per	rson		Date						

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The shares sold were pursuant to a Rule 10b5-1 plan dated March 17, 2011. The transaction was executed in multiple trades in prices ranging from \$8.02 to \$8.62 inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.

- (2) These shares are held by the Drmanac Family Trust dated June 21, 2000, Radoje Drmanac, Trustee.
- (3) These shares are held by Callida Genomics, Inc., a corporation wholly owned by the Reporting Person and his wife.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.